Sanjivani Paranteral Reports Positive Q2 Results, Net Sales and Profitability on the Rise

Sanjivani Paranteral, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.

According to the financial report, Sanjivani Paranteral has shown positive performance in the second quarter of the fiscal year 2024-2025. The company's score has improved from 14 to 9 in the last three months.

One of the key factors contributing to this positive performance is the increase in net sales. In the last five quarters, the company's net sales have reached a high of Rs 18.13 crore, showing a growth of 24.5% compared to the average net sales of the previous four quarters. This trend is expected to continue in the near term.

Sanjivani Paranteral has also shown a strong operating profit (PBDIT) in the last five quarters, with the highest being Rs 2.86 crore. The company's profit before tax (PBT) and profit after tax (PAT) have also reached their highest levels in the last five quarters, at Rs 2.53 crore and Rs 2.30 crore respectively. This indicates a positive trend in the company's profitability and its ability to generate higher earnings for shareholders.

However, the company's operating cash flow has been a cause for concern. It has been consistently falling in the last three years, with the lowest being Rs -10.70 crore in the last fiscal year. This suggests that the company's cash revenues from business operations are declining.

Overall, Sanjivani Paranteral has shown a positive financial performance in the recent quarter, with strong net sales and profitability. However, the company needs to address its declining operating cash flow in order to sustain its growth in the long term.